Logan Lutton

Advances in HIV medication, its window of detection and its transmission risk within the last decade have led to an updated version of the HIV exposure protocol for healthcare personnel.

Elevated levels of the gut hormone GLP-1 and its receptor may worsen brain inflammation and trigger severe symptoms in patients with neuromyelitis optica spectrum disorder (NMOSD), suggesting GLP-1 drugs could pose risks for this rare autoimmune disease.

Results show that GLP-1s may address rheumatoid arthritis (RA) symptoms, independent of established weight loss and cardiac benefits, by reducing the systemic, chronic inflammation associated with RA.

Here’s what you missed this week on Managed Healthcare Executive.

Illuminate Rx is the country’s first pharmacist-designed pharmacy benefits optimizer (PBO), offering transparent, clinically driven PBM options for brokers and self-funded employers, with a focus on data clarity, flexible formulary design and specialty pharmacy partnerships, according to Robert Gamble, CEO of RxBenefits.

Diagnosed with triple-negative breast cancer at age 36 and now in remission, Deanna Gerber, M.D., gynecologic oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, says her experience has made her a better physician and advocate for her patients.

A decline in PrEP coverage could reverse HIV prevention gains, causing tens of thousands of preventable infections and billions in added healthcare costs, a new JAMA Network Open study finds.

The new JAMA + Women’s Health multimedia channel focuses on all aspects of women’s health, not just topics like menopause or ovarian cancer, presenting content from across JAMA and JAMA Network in one place.

Use of transparent PBMs has surged as employer reliance on the Big Three declines, highlighting shifting strategies to address escalating healthcare costs, the Pulse of the Purchaser 2025 survey finds.

Ongoing research is needed to further explore the best methods for anal cancer detection in people living with HIV, according to a recent review.

For someone with HIV, a mental health disorder may decrease their life expectancy by as many as five years, according to the results of a recent international study.

Here’s what you missed this week on Managed Healthcare Executive.

Gen Z workers have a less positive outlook about the healthcare field than their older counterparts, according to the results of a new national survey by WellSky.

Vertically integrated health plans are starting to fall by the wayside due to their limited flexibility, while modular health plans are gaining traction, according to Scott Rossignol, senior director of Drug Value Strategy at Abarca Health.

Health Secretary Robert F. Kennedy Jr. faces bipartisan scrutiny over vaccine policies, Medicare costs and rural healthcare during a Senate hearing.

Act 624 and ambiguous ERISA policies are some of the biggest issues faced by pharmacy benefit leaders today, according to Robyn Crosson, vice president of government relations, Navitus Health Solutions.

Pharmacy and medical benefit programs have traditionally operated separately, despite having similarities. Nishi Goel, Pharm.D., vice president of customer experience, Agadia, is trying to change that.

The growing trend of at-home drug administration emphasizes the need for integrated medical and pharmacy reviews, according to Nishi Goel, Pharm.D., vice president of customer experience, Agadia.

Although Medicare Advantage plan member satisfaction has dropped, areas for improvement have emerged in the form of digital innovations, according to the J.D. Power 2025 U.S. Medicare Advantage Study.

Here’s what you missed this week on Managed Healthcare Executive.

The next step for the Rise For Health study researchers is to study the health benefits of frequent standing in older men and women.

Sexual and gender minority individuals still face insurance denials and cost-sharing barriers when accessing pre-exposure prophylaxis (PrEP), despite having a Grade A recommendation from the United States Preventive Services Task Force (USPSTF).

The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.

Large language models (LLMs) were more likely to suggest inferior treatment options when reviewing hypothetical cases when patients' Black identity was listed or implied.

New study results provide insight into improving heart health through behavior changes, such as taking standing breaks throughout the day.

A lack of training and vague, overlapping symptoms can be attributed to more than three-quarters of autoimmune patients being misdiagnosed at least once, according to Veena Joy, the U.S. Lead for Strategic Partnerships, Allergy and Autoimmunity at Thermo Fisher Scientific.

Prefilled syringes of Imuldosa now have the lowest wholesaler acquisition cost among all branded ustekinumab biosimilars, according to a news release.

Tonmya is the first new fibromyalgia treatment approved by the FDA in more than 15 years, providing symptom relief for at least 30% of patients when compared to placebo, according to clinical trial results.

Here’s what you missed this week on Managed Healthcare Executive.

Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ongoing clinical studies showing symptom relief for up to two years.